Literature DB >> 18165268

Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization.

Cornelia Stock1, Eva Bozsaky, Franz Watzinger, Ulrike Poetschger, Lukas Orel, Thomas Lion, Agata Kowalska, Peter F Ambros.   

Abstract

MYCN amplification is associated with poor prognosis in neuroblastoma disease. To improve our understanding of the influence of the MYCN amplicon and its corresponding expression, we investigated the 2p expression pattern of MYCN amplified (n = 13) and nonamplified (n = 4) cell lines and corresponding primary tumors (n = 3) using the comparative expressed sequence hybridization technique. All but one MYCN amplified cell line displayed overexpression at 2p. Expression peaks were observed frequently at 2pter and less frequently at 2p24 (MYCN locus), 2p23.3-23.2, and/or 2p23.1. Importantly, cell lines and two corresponding primary tumors displayed expression peaks at similar loci. No significant 2p24 expression level was observed for those cell lines displaying a low amplification rate (n = 3) by comparative genomic hybridization. Only the cell lines with an enhanced peak at 2p23.2-23.3 displayed coamplification of the ALK gene (2p23.2), reported to be associated with unfavorable prognosis. Finally, two of four cell lines without MYCN amplification, both derived from patients with poor outcome, also showed an expression peak at 2p23.2. These data indicate that, besides MYCN, other genes proximal and distal to MYCN are highly expressed in neuroblastoma. The prognostic significance of expression peaks at 2p23.2-23.3, independent of MYCN and ALK status, remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18165268      PMCID: PMC2189624          DOI: 10.2353/ajpath.2008.061263

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  55 in total

1.  Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors.

Authors:  C M Hattinger; S Rumpler; S Strehl; I M Ambros; A Zoubek; U Pötschger; H Gadner; P F Ambros
Journal:  Genes Chromosomes Cancer       Date:  1999-03       Impact factor: 5.006

2.  No evidence for correlation of DDX1 gene amplification with improved survival probability in patients with MYCN-amplified neuroblastomas.

Authors:  Katleen De Preter; Frank Speleman; Valérie Combaret; John Lunec; Julian Board; Andy Pearson; Anne De Paepe; Nadine Van Roy; Geneviève Laureys; Jo Vandesompele
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

3.  High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.

Authors:  Yael P Mosse; Joel Greshock; Adam Margolin; Tara Naylor; Kristina Cole; Deepa Khazi; George Hii; Cynthia Winter; Syed Shahzad; Muhammad Usman Asziz; Jaclyn A Biegel; Barbara L Weber; John M Maris
Journal:  Genes Chromosomes Cancer       Date:  2005-08       Impact factor: 5.006

Review 4.  Measurement and relevance of neuroblastoma DNA copy number changes in the post-genome era.

Authors:  Yael P Mosse; Joel Greshock; Barbara L Weber; John M Maris
Journal:  Cancer Lett       Date:  2005-10-18       Impact factor: 8.679

5.  Biological role of anaplastic lymphoma kinase in neuroblastoma.

Authors:  Yuko Osajima-Hakomori; Izumi Miyake; Miki Ohira; Akira Nakagawara; Atsuko Nakagawa; Ryuichi Sakai
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

6.  Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas.

Authors:  Johannes H Schulte; Alexander Schramm; Ludger Klein-Hitpass; Michael Klenk; Hendrika Wessels; Berthold P Hauffa; Jürgen Eils; Roland Eils; Garrett M Brodeur; Lothar Schweigerer; Werner Havers; Angelika Eggert
Journal:  Oncogene       Date:  2005-01-06       Impact factor: 9.867

7.  Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes.

Authors:  Isabelle Vanden Bempt; Vera Vanhentenrijk; Maria Drijkoningen; Christiane De Wolf-Peeters
Journal:  J Pathol       Date:  2006-03       Impact factor: 7.996

8.  Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

Authors:  Alexander Schramm; Johannes H Schulte; Ludger Klein-Hitpass; Werner Havers; Hauke Sieverts; Bernd Berwanger; Holger Christiansen; Patrick Warnat; Benedikt Brors; Jürgen Eils; Roland Eils; Angelika Eggert
Journal:  Oncogene       Date:  2005-11-24       Impact factor: 9.867

Review 9.  Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.

Authors:  S B Bordow; M D Norris; P S Haber; G M Marshall; M Haber
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

10.  MYCN protein expression as a predictor of neuroblastoma prognosis.

Authors:  H S Chan; B L Gallie; G DeBoer; G Haddad; N Ikegaki; J Dimitroulakos; H Yeger; V Ling
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

View more
  8 in total

1.  BIRC5/Survivin as a target for glycolysis inhibition in high-stage neuroblastoma.

Authors:  J Hagenbuchner; U Kiechl-Kohlendorfer; P Obexer; M J Ausserlechner
Journal:  Oncogene       Date:  2015-07-06       Impact factor: 9.867

2.  2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.

Authors:  Marta Jeison; Shifra Ash; Gili Halevy-Berko; Jacques Mardoukh; Drorit Luria; Smadar Avigad; Galina Feinberg-Gorenshtein; Yacov Goshen; Gabriel Hertzel; Joseph Kapelushnik; Ayelet Ben Barak; Dina Attias; Ran Steinberg; Jerry Stein; Batia Stark; Isaac Yaniv
Journal:  Am J Pathol       Date:  2010-04-15       Impact factor: 4.307

3.  Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure.

Authors:  Clelia Tiziana Storlazzi; Angelo Lonoce; Maria C Guastadisegni; Domenico Trombetta; Pietro D'Addabbo; Giulia Daniele; Alberto L'Abbate; Gemma Macchia; Cecilia Surace; Klaas Kok; Reinhard Ullmann; Stefania Purgato; Orazio Palumbo; Massimo Carella; Peter F Ambros; Mariano Rocchi
Journal:  Genome Res       Date:  2010-07-14       Impact factor: 9.043

4.  Kidins220/ARMS is expressed in neuroblastoma tumors and stabilizes neurotrophic signaling in a human neuroblastoma cell line.

Authors:  Danny A Rogers; Nina F Schor
Journal:  Pediatr Res       Date:  2013-09-02       Impact factor: 3.756

5.  Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma.

Authors:  Judith Hagenbuchner; Martina Rupp; Christina Salvador; Bernhard Meister; Ursula Kiechl-Kohlendorfer; Thomas Müller; Kathrin Geiger; Consolato Sergi; Petra Obexer; Michael J Ausserlechner
Journal:  Oncotarget       Date:  2016-11-22

6.  The tubulin inhibitor MG-2477 induces autophagy-regulated cell death, ROS accumulation and activation of FOXO3 in neuroblastoma.

Authors:  Judith Hagenbuchner; Lorena Lungkofler; Ursula Kiechl-Kohlendorfer; Giampietro Viola; Maria Grazia Ferlin; Michael J Ausserlechner; Petra Obexer
Journal:  Oncotarget       Date:  2017-05-09

7.  Schwann cell plasticity regulates neuroblastic tumor cell differentiation via epidermal growth factor-like protein 8.

Authors:  Tamara Weiss; Sabine Taschner-Mandl; Lukas Janker; Andrea Bileck; Fikret Rifatbegovic; Florian Kromp; Helena Sorger; Maximilian O Kauer; Christian Frech; Reinhard Windhager; Christopher Gerner; Peter F Ambros; Inge M Ambros
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

8.  Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification.

Authors:  Gisela Lundberg; Anders H Rosengren; Ulf Håkanson; Henrik Stewénius; Yuesheng Jin; Ylva Stewénius; Sven Påhlman; David Gisselsson
Journal:  PLoS One       Date:  2008-08-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.